Genalyte, Collaborators Gear Up for Phase Two of Tumor-associated Antigen Panel Development

Feb 03, 2015

|

Premium

NEW YORK (GenomeWeb) – Having completed the first phase of a $1 million National Cancer Institute grant to develop a panel of tumor-associated antibodies (TAAs) to help detect cancer and assess patient response to immune-modulating cancer drugs, Genalyte is now gearing up to manufacture a set of chips covering this panel to support the second phase of the project.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Scott Gottlieb Goes Back to His Old Job

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Where No CRISPR Has Gone Before

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Two Leave Emory

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

This Week in Science

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.

Featured White Papers

Compatibility of liquid biopsy assays on multiple sequencing platforms

Optimized NGS Library Preparation with Acoustic Liquid Handling

Jun

06

Featured Webinar

Accelerating Crop Research with High-Quality Affordable Genome Assemblies

This webinar will discuss the impact of affordable de novo genome assemblies on crop research.

Jun

18

Featured Webinar

Clinical Genomics of NTRK Fusion Detection in Cancer

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect.

Menu